Investing in Longevity: Where Crypto and Biotech Meet

The idea of living longer and healthier is no longer just a dream. It's becoming a reality, thanks to the science of longevity. This field is getting serious attention from big investors like Jeff Bezos and Mark Zuckerberg. It's like the crypto world, where new ideas can change everything. LongeVC is a venture fund that invests in longevity biotech. Their first fund was a success, backing 20 companies, including two unicorns. Now, they're launching a second fund with a twist: they accept investments in stablecoins. Sergey Jakimov, the managing partner of LongeVC, shares their strategy. They focus on early-stage therapeutics, diagnostics, and AI for drug discovery. They call this "longevity infrastructure. " The first fund was $25 million, but the second one will be $120 million. This time, they can invest more in each company, speeding up product development. LongeVC is also bridging the gap between crypto and biotech. They accept stablecoins, making it easier for crypto investors to join. This is a big deal because biotech is usually conservative, but crypto is all about innovation. The global aging population and the multibillion-dollar longevity market guide their investments. They focus on diseases like cancer, neurodegeneration, and cardiovascular diseases. They also invest in prevention and longevity infrastructure, like AI for drug design and preventive healthcare. The involvement of tech titans like Sam Altman and Jeff Bezos is changing perceptions. It shows that longevity is becoming mainstream. It also elevates other companies in the space, making them more known. But how do they align the crypto community's expectations with the long timelines of biotech? They understand that biotech investments take time. A successful exit can take 2-4 years, with a target multiple of over 6-7x. Looking ahead, they see a world where crypto capital powers longevity breakthroughs. This means more capital for science, speeding up patient outcomes. They believe crypto can be a nimble and efficient capital source, which is often scarce in biotech.